| ERCC5 (XPG) | |
|---|---|
| Full Name | Excision Repair Cross-Complementation Group 5 (XPG endonuclease) |
| Gene Symbol | ERCC5 |
| Alternate Symbols | XPG, UV-DDB, UVSSP |
| Chromosomal Location | 13q33.2 |
| NCBI Gene ID | 6148 |
| OMIM | 133530 |
| Ensembl ID | ENSG00000134899 |
| UniProt ID | Q15772 |
| Protein Length | 1,186 amino acids |
| Category | DNA Repair/Nucleotide Excision Repair |
ERCC5 (Excision Repair Cross-Complementation Group 5), also known as XPG, is a critical DNA repair gene that encodes a structure-specific endonuclease essential for nucleotide excision repair (NER). The XPG protein plays a fundamental role in maintaining genomic integrity by excising bulky DNA adducts and UV-induced photoproducts that would otherwise cause mutations and cell death [@ncbi].
ERCC5 was originally identified through complementation studies in xeroderma pigmentosum (XP) patients, where fibroblasts from XP-G complementation group failed to perform NER. Subsequent research has revealed that ERCC5 deficiency causes not only XP but also Cockayne syndrome (CS) in compound heterozygotes, and is associated with a spectrum of neurodegenerative conditions including cerebellar ataxia, peripheral neuropathy, and accelerated aging phenotypes [@maddukuri2022].
The discovery of ERCC5 variants in neurodegenerative diseases beyond XP/CS has highlighted the broader importance of DNA repair capacity in maintaining neuronal health. With the aging population and increased prevalence of neurodegenerative disorders, understanding how ERCC5 and other DNA repair genes contribute to neuronal survival has become a critical area of research [@jacobs2015].
XPG is a large protein (1,186 amino acids) with a modular domain architecture that enables its specialized endonuclease function:
| Domain | Location | Function |
|---|---|---|
| N-terminal Region | 1-400 aa | Protein-protein interactions, regulatory functions |
| Nuclease Domain | 400-800 aa | Catalytic endonuclease activity |
| Helix-hairpin-helix (HhH) | 800-1000 aa | DNA binding, structural stability |
| Iron-sulfur cluster (4Fe-4S) | 950-1050 aa | DNA binding, structural |
| C-terminal Region | 1050-1186 aa | Interaction with TFIIH complex |
The catalytic core of XPG contains the active site responsible for DNA cleavage:
High-resolution crystal structures have revealed the molecular basis of XPG's function:
XPG is a key component of the NER pathway, which removes bulky DNA lesions that distort the helix:
| NER Sub-pathway | Role of XPG |
|---|---|
| Global Genome NER (GG-NER) | Scans DNA for lesions across the genome |
| Transcription-Coupled NER (TC-NER) | Removes lesions from actively transcribed genes |
| Dual incision | Makes 3' incision 6-8 nucleotides from lesion |
| DNA synthesis | Gap filling by polymerases δ, ε, κ |
| Ligation | Seals the repaired strand |
The specific incision reaction catalyzed by XPG:
XPG interacts with multiple proteins in the NER complex:
| Partner | Function | Interaction Domain |
|---|---|---|
| XPC-RAD23B | Lesion recognition | N-terminal region |
| TFIIH | DNA unwinding | Central catalytic domain |
| XPA | Damage verification | C-terminal region |
| XPF-ERCC1 | 5' incision partner | Direct protein interaction |
| RPA | Single-strand binding | Competitive binding |
| PCNA | Replication clamp | C-terminal interaction |
Neurons face unique challenges regarding DNA damage:
Studies in mice and cellular models demonstrate the importance of XPG in neuronal health:
XPG plays a critical role in repairing oxidative DNA damage:
XP is an autosomal recessive disorder characterized by:
| Feature | Description |
|---|---|
| Sunlight sensitivity | Extreme UV sensitivity leading to sunburn |
| Pigmentation changes | Freckling, hyperpigmentation in sun-exposed areas |
| Cancer predisposition | 10,000-fold increased risk of skin cancers |
| Neurological degeneration | Progressive neurodegeneration in many patients |
XP-G patients have biallelic ERCC5 mutations that result in partial or complete loss of nuclease activity. Genotype-phenotype correlations show that mutations preserving some catalytic activity lead to milder phenotypes [@lehmann1995].
Compound heterozygous ERCC5 mutations can cause features of Cockayne syndrome:
The CS phenotype suggests that XPG's role in transcription-coupled repair is particularly important for neuronal function [@maddukuri2022].
Beyond classic DNA repair disorders, ERCC5 variants have been implicated in:
| Disease | Evidence | Mechanism |
|---|---|---|
| Alzheimer's disease | GWAS signals, expression changes | Impaired DNA repair capacity |
| Parkinson's disease | Rare variants, reduced expression | Mitochondrial DNA damage accumulation |
| Amyotrophic lateral sclerosis | Rare coding variants | Cumulative DNA damage |
| Ataxia | Autosomal recessive variants | Cerebellar neuron loss |
The primary disease mechanism in ERCC5 deficiency:
DNA damage accumulation affects neurons through multiple pathways:
Cells and organisms have attempted compensatory responses:
The balance between these responses determines whether XPG-deficient cells survive or die [@hoeijmakers2009].
Given that ERCC5 deficiency is caused by loss-of-function mutations, gene replacement is a logical therapeutic approach:
| Strategy | Status | Challenge |
|---|---|---|
| AAV vectors | Preclinical | Delivery to neurons, expression levels |
| CRISPR-based correction | Research | Repair efficiency, off-target effects |
| mRNA delivery | Discovery | Delivery, duration of expression |
| Protein therapy | Preclinical | BBB penetration, stability |
DNA repair capacity can potentially be enhanced pharmacologically:
Several challenges face therapeutic development:
ERCC5/XPG interacts with multiple proteins relevant to neurodegeneration:
| Interactor | Function | Relevance |
|---|---|---|
| XPC (RAD23B) | Global genome NER | Lesion recognition |
| TFIIH complex | Transcription/repair | DNA unwinding |
| XPA | Damage verification | Damage site selection |
| XPF-ERCC1 | 5' incision | Complementary incision |
| RPA | Single-strand protection | Prevents further damage |
| PCNA | Replication clamp | DNA synthesis |
| p53 | DNA damage response | Cell fate decisions |
| ATR | Replication stress response | Checkpoint activation |
ERCC5 shows differential expression across brain cell types:
| Cell Type | Expression Level | Notes |
|---|---|---|
| Neurons | High | Active transcription requires robust repair |
| Astrocytes | Moderate | Support cells with DNA repair capacity |
| Microglia | Moderate | Immune cells with DNA damage response |
| Oligodendrocytes | Moderate | Myelinating cells |
| Neural stem cells | Very High | Active proliferation requires repair |
ERCC5 expression changes during development:
| Gene | Primary Function | ERCC5 Relationship |
|---|---|---|
| ERCC1 | 5' incision in NER | Direct partner in NER |
| XPC | Lesion recognition | Initiates GG-NER |
| XPA | Damage verification | Coordinates repair |
| XPD (ERCC2) | TFIIH helicase | Part of same complex |
| XPF | 5' incision | Partner endonuclease |
| OGG1 | Base excision repair | Complementary pathway |
| TDP1 | Repair of topoisomerase lesions | Separate repair pathway |